CADL
NASDAQ
US
Candel Therapeutics, Inc. - Common Stock
$5.00
▲ +$0.02
(+0.40%)
Vol 901K
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$310.2M
ROE
-29.2%
Margin
-15156.5%
D/E
6.49
Beta
-0.87
52W
$4–$14
Wall Street Consensus
14 analysts · Apr 20264
Strong Buy
8
Buy
2
Hold
0
Sell
0
Strong Sell
85.7%
Buy Rating
Price Chart
Similar Stocks
GNLX
Genelux Corp
$165.9M
SGMO
Sangamo Therapeutics Inc
$141.3M
BMEA
Biomea Fusion Inc
$87.7M
KPTI
Karyopharm Therapeutics Inc
$125.5M
CRDF
Cardiff Oncology Inc
$189.3M
ALDX
Aldeyra Therapeutics Inc
$99.9M
SPRB
Spruce Biosciences, Inc
$93.2M
COYA
Coya Therapeutics Inc
$121.4M
QTTB
Q32 Bio Inc
$40.9M
Earnings
Beat rate: 40.0%
Next Report
May 11, 2026
EPS Estimate: $-0.34
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.34 | — | — |
| Dec 2025 | $-0.25 | $-0.54 | $-0.29 |
| Sep 2025 | $-0.19 | $-0.21 | $-0.02 |
| Jun 2025 | $-0.17 | $-0.09 | +$0.08 |
Quarterly Revenue & Earnings
| Quarter | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -$14.1M | $7.4M | -$4.8M | -$11.3M | -$29.5M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -14.9% | -14.9% | -14.9% | -14.9% | -14.9% | -29.2% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | -15156.5% | -15156.5% | -15156.5% | -15156.5% | -15156.5% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 8.47 | 8.47 | 8.47 | 8.47 | 8.47 | 6.49 |
| Current Ratio | 7.04 | 7.04 | 7.04 | 7.04 | 7.04 | 8.25 |
Key Ratios
ROA (TTM)
-22.6%
P/S (TTM)
2501.41
P/B
5.5
EPS (TTM)
$-0.56
CF/Share
$-1.07
52W High
$13.68
52W Low
$4.25
$4.25
52-Week Range
$13.68
Financial Health
Free Cash Flow
-$11.0M
Net Debt
-$70.7M
Cash
$119.7M
Total Debt
$49.0M
As of Dec 31, 2025
How does CADL compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
CADL valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
2501.4
▲
19366%
above
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
5.5
▲
124%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
CADL profitability vs Biotechnology peers
ROE
-29.2%
▲
57%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
-15156.5%
▼
5186%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-22.6%
▲
52%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
CADL financial health vs Biotechnology peers
D/E ratio
6.5
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
8.3
▲
86%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
-0.9
▼
190%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
CADL fundamentals radar
CADL
Peer median
Industry
CADL profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
CADL vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
MANNING PAUL B.
Director · Feb 23
550458 shs
Last 90 days
Top Holders
Top 5: 24.13%FMR, LLC
11.24%
$39.6M
Blackrock Inc.
3.91%
$13.8M
Acorn Capital Advisors, LLC…
3.52%
$12.4M
Vanguard Group Inc
3.15%
$11.1M
Portolan Capital Management…
2.31%
$8.2M
As of Dec 31, 2025
Latest News
No related news yet